Download PDF
Z Gastroenterol 2020; 58(05): 431-438
DOI: 10.1055/a-1135-9306
Originalarbeit

Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment

Populationsbasierte Analyse von autoimmuner Hepatitis und primär biliärer Cholangitis in Deutschland: ansteigende Prävalenzen basierend auf ICD Codes, aber Defizite bei der medikamentösen Therapie
Marcial Sebode
1   I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2   European Reference Network on Rare Hepatological Diseases (ERN RARE-LIVER).
,
Angela Kloppenburg
3   Techniker Krankenkasse, Hamburg, Germany
,
Annette Aigner
4   Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
5   Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, Berlin, Germany
,
Ansgar W. Lohse
1   I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2   European Reference Network on Rare Hepatological Diseases (ERN RARE-LIVER).
,
Christoph Schramm   *
1   I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2   European Reference Network on Rare Hepatological Diseases (ERN RARE-LIVER).
6   Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
,
Roland Linder   *
3   Techniker Krankenkasse, Hamburg, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Population-based data on the prevalence of and real-life treatment for the autoimmune liver diseases (AILD), primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH), are scarce, and such knowledge may help to improve patient care.

Methods Data of 8.1 million individuals having health insurance with the “Techniker Krankenkasse,” the largest German health insurer, were analyzed with regard to the prevalence of and prescribed medication for AILD in Germany from 2011 until 2014. Patients with viral hepatitis B infection (HBV) and alcoholic liver cirrhosis (ALC) served as control groups. Case definition was based on ICD codes.

Results The prevalences of PBC and AIH were 36.9/100 000 inhabitants (95 % CI: 35.6–38.2) and 23.0/100 000 inhabitants (95 % CI: 22.0–24.0) in 2014, respectively. The prevalences of AILD increased from 2011 to 2014 (for PBC by 31 % and for AIH by 29 %), with the largest increase for male patients with PBC. In contrast, the prevalence of HBV declined while that of ALC remained stable. The analysis of prescribed real-life treatment revealed considerable deviations from standard treatment recommendations. Specifically, in older patients with PBC or AIH, undertreatment was common.

Conclusion The prevalence of PBC and AIH based on ICD codes is increasing in Germany. The analysis of real-life treatment in this large and population-based cohort points to the unmet need to improve the implementation of treatment guidelines for autoimmune liver diseases in the broader medical community.

Zusammenfassung

Hintergrund Es gibt nur wenige populationsbasierte Studien zur Prävalenz und zur „Real-Life“-Therapie der autoimmunen Lebererkrankungen Primär Biliäre Cholangitis (PBC) und Autoimmune Hepatitis (AIH).

Methoden Es wurden 8,1 Millionen Versichertendaten der Techniker Krankenkasse analysiert bezüglich der Prävalenz und rezeptierten Medikation von Patienten mit autoimmunen Lebererkrankungen in Deutschland von 2011 bis 2014. Patienten mit einer Virushepatitis-B-Infektion (HBV) und mit alkoholischer Leberzirrhose (C2 LZX) dienten als Kontrollgruppen. Die Patienten wurden anhand von ICD-Codes identifiziert.

Ergebnisse Die PBC und die AIH weisen in Deutschland im Jahr 2014 eine Prävalenz von 36,9 pro 100 000 Einwohner (95 %-KI: 35,6–38,2) beziehungsweise 23,0 pro 100 000 Einwohner (95 %-KI: 22,0–24,0) auf. Die Prävalenz autoimmuner Lebererkrankungen stieg von 2011 bis 2014 an (für die PBC um 31 % und für die AIH um 29 %), wobei männliche PBC-Patienten den stärksten Anstieg aufwiesen. Die Prävalenz von HBV und C2 LZX nahm ab beziehungsweise blieb stabil. Eine Analyse der „Real-Life“-Therapie der autoimmunen Lebererkrankungen ergab erhebliche Abweichungen von Therapieleitlinien; insbesondere bei älteren AIH- und PBC-Patienten lag eine Untertherapie vor.

Schlussfolgerung Die Prävalenz der PBC und AIH basierend auf ICD-Codes steigt in Deutschland an. Die populationsbasierte Analyse der „Real-Life“-Therapie autoimmuner Lebererkrankungen in Deutschland weist auf Defizite in der breiten medizinischen Versorgung hinsichtlich der Umsetzung von Therapieleitlinien hin.

Key words

autoimmune hepatitis - primary biliary cholangitis - Germany - treatment - prevalence

Schlüsselwörter

autoimmune Jepatitis - Primär Biliäre Cholangitis - Deutschland - Therapie - Prävalenz

* Shared senior authorship.




Publication History

Received: 16 November 2019

Accepted: 05 March 2020

Article published online:
11 May 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Jepsen P, Grønbæk L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis 2015; 33: 2-12
    PubMedGoogle Scholar
  • 2 European Association for the Study of the Liver. EASL clinical practice guidelines. The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67: 145-172
    CrossrefPubMedGoogle Scholar
  • 3 Carbone M, Mells GF, Pells G. et al. Sex and age are determinants of the clinical notype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144: 560-569
    CrossrefPubMedGoogle Scholar
  • 4 Lleo A, Jepsen P, Morenghi E. et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep 2016; 6: 25906
    CrossrefPubMedGoogle Scholar
  • 5 European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267
    CrossrefPubMedGoogle Scholar
  • 6 Corpechot C, Carrat F, Bonnand AM. et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-1199
    CrossrefPubMedGoogle Scholar
  • 7 Corpechot C, Carrat F, Bahr A. et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303
    CrossrefPubMedGoogle Scholar
  • 8 European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015; 63: 971-1004
    CrossrefPubMedGoogle Scholar
  • 9 Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612-617
    CrossrefPubMedGoogle Scholar
  • 10 Van Gerven NM, Verwer BJ, Witte BI. et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013; 58: 141-147
    CrossrefPubMedGoogle Scholar
  • 11 Manns MP, Woynarowski M, Kreisel W. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
    CrossrefPubMedGoogle Scholar
  • 12 Deutsche Gesellschaft Fur Gastroenterologie, V.-U.S., Deutsche Gesellschaft Fur Innere, et al. Practice guideline autoimmune liver diseases; AWMF-Reg. No. 021-27. Z Gastroenterol 2017; 55: 1135-1226
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-1188
    CrossrefPubMedGoogle Scholar
  • 14 Boonstra K, Kunst AE, Stadhouders PH. et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int 2014; 34: e31-e38
    CrossrefPubMedGoogle Scholar
  • 15 Kim KA, Ki M, Choi HY. et al. Population-based epidemiology of primary biliary cirrhosis in South Korea. Aliment Pharmacol Ther 2016; 43: 154-162
    CrossrefPubMedGoogle Scholar
  • 16 Van Gerven NM, Verwer BJ, Witte BI. et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014; 49: 1245-1254
    CrossrefPubMedGoogle Scholar
  • 17 Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413
    CrossrefPubMedGoogle Scholar
  • 18 R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017 http://www.R-project.org/
    PubMedGoogle Scholar
  • 19 Dorai-Raj U. Binom: binomial confidence intervals for several parameterizations. R package version 1.1-1. 2014 https://CRAN.R-project.org/package=binom
    PubMedGoogle Scholar
  • 20 Swart E, Bitzer EM, Gothe H. et al. A consensus German reporting standard for secondary data analyses, version 2 (STROSA-STandardisierte BerichtsROutine für SekundärdatenAnalysen). Gesundheitswesen 2016; 78: e145-e160
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Swart E, Gothe H, Geyer S. et al. Good practice of secondary data analysis (GPS): guidelines and recommendations. Gesundheitswesen 2015; 77: 120-126
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Schulz M, Wandrey M, Hering R. et al. Prävalenz seltener Erkrankungen in der ambulanten Versorgung in Deutschland im Zeitraum 2008 bis 2011. Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi), Versorgungsatlas-Bericht Nr. 15/13. Berlin: 2015 http://www.versorgungsatlas.de/themen/alle-analysen-nach-datum-sortiert/?tab=6&uid=63
    PubMedGoogle Scholar
  • 23 Guthoff-Hagen S. PBC 2015—Epidemiologische Auswertungen. 2016
    PubMedGoogle Scholar
  • 24 Gordon V, Adhikary R, Appleby V. et al. Diagnosis, presentation and initial severity of autoimmune hepatitis (AIH) in patients attending 28 hospitals in the UK. Liver Int 2018; 38: 1686-1695
    CrossrefPubMedGoogle Scholar
  • 25 Lu M, Zhou Y, Haller IV. et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol 2018; 16: 1342-1350
    CrossrefPubMedGoogle Scholar
  • 26 Lu M, Li J, Haller IV. et al. Factors associated with prevalence and treatment of primary biliary cholangitis in United States Health Systems. Clin Gastroenterol Hepatol 2018; 16: 1333-1341
    CrossrefPubMedGoogle Scholar
  • 27 Boberg KM, Chapman RW, Hirschfield GM. et al. International Autoimmune Hepatitis Group. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385
    CrossrefPubMedGoogle Scholar
  • 28 Janik MK, Wunsch E, Raszeja-Wyszomirska J. et al. Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: a prospective, single-centre study. Liver Int 2019; 39: 215-221
    CrossrefPubMedGoogle Scholar
  • 29 Wong LL, Fisher HF, Stocken DD. et al. The impact of autoimmune hepatitis and its treatment on health utility. Hepatology 2018; 68: 1487-1497
    CrossrefPubMedGoogle Scholar
  • 30 Schramm C, Kanzler S, zum Büschenfelde KH. et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96: 1587-1591
    CrossrefPubMedGoogle Scholar
  • 31 Al-Chalabi T, Boccato S, Portmann BC. et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45: 575-583
    CrossrefPubMedGoogle Scholar
  • 32 Dyson JK, Wong LL, Bigirumurame T. et al. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Aliment Pharmacol Ther 2018; 48: 951-960
    CrossrefPubMedGoogle Scholar